Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
about
Design and pre-clinical evaluation of a universal HIV-1 vaccineSynthetic DNA vaccine strategies against persistent viral infectionsImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesEvolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targetsHuman immunodeficiency virus vaccine trialsHIV-1 Vaccine Trials: Evolving Concepts and DesignsHuman immunodeficiency virus vaccine an update.The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT.A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesDual neonate vaccine platform against HIV-1 and M. tuberculosis.Protective efficacy of serially up-ranked subdominant CD8+ T cell epitopes against virus challengesDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.DNA/MVA Vaccines for HIV/AIDSSafety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteersCD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individualsPhase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.Creating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infantsPedVacc 002: a phase I/II randomized clinical trial of MVA.HIVA vaccine administered to infants born to human immunodeficiency virus type 1-positive mothers in Nairobi.Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adultsVaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against LeishmaniaReplicating and non-replicating viral vectors for vaccine developmentKinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responsesDelivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responsesBroad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapyA new era in HIV vaccine development.Current progress of DNA vaccine studies in humans.Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects
P2860
Q21092234-77D84410-8464-475C-9E05-7A07976E4173Q27016078-06ECD4A4-2D22-4C47-BA30-65BEFBB5575EQ27319783-1092EA4D-8C85-44CC-8117-9F3A3D845D0AQ30366017-65E7958B-8531-410D-ADC1-D308DF192257Q30424366-9F615B91-9E8F-4FB8-9907-23C61D5CE529Q30425520-0CFDC301-0BAB-48D7-BF38-11E71222D98FQ30432382-71AA298C-64B6-4147-9A4A-FA94E37A7F42Q30484153-CFED4EB5-337A-498A-8C76-E1CC27122C68Q30934059-C69867B7-6908-48B6-9C4B-C94B30229866Q33320536-6B64550A-1E7C-41C6-BCEC-0AD0002D2EF0Q33401609-97F45B6D-05F5-4404-B997-DCC951EC226BQ33578049-2E2E7377-5D1E-48C1-B974-AA7E2F2C98AAQ33877458-A015FDD4-E24E-4593-850B-C7994BB3D3BBQ33908584-63777485-EECE-486F-9A2C-1AA17B0F9657Q33916635-6EED1421-3B71-4CCA-95B0-FA2B78FE4BD8Q33916776-336C0F35-030D-427C-8073-29198E3406CFQ33967039-C56FB44E-1A11-42D1-8CDF-BD9DA8494731Q34128200-B96E037A-4050-4B94-8F37-8BA3758ED9DEQ34188729-DDA8DAB6-B8AE-45E6-9CF6-05BBCBAC36B5Q34205476-7B9854EC-CB51-4688-B24D-562AC71EA8ECQ34492802-FFBF800C-24B4-4A4D-99F4-84D45FA7E35DQ34589611-69307639-06CD-4B39-96A9-BEBB8B6C4ADFQ34692141-84D327AE-87F3-456C-A14C-1EF40946764CQ34772727-36451F54-D530-45E5-B925-D9ABADEB3054Q34989509-0D017966-1604-45CD-8706-45753AEA9C3AQ35036289-6475BDF4-AC32-41E4-ADBA-4DC8B880BAD2Q35554825-4EA37D1B-C95B-4C6D-9A0F-E550DCA3D080Q35571248-8C80F697-70AB-42E4-942E-8E85E6DD922CQ35641132-9FFB9491-1561-4053-99AC-929BD58DC6B8Q35940696-0F304511-9B79-42C9-A04C-1FA0A321E0F0Q35947967-0382208B-D22E-40A3-B0DC-6EE6676C156AQ36251325-C9C17293-C1CE-418B-851A-99FC309BDED5Q36464587-A8415204-A94C-4C3D-AF98-F7267D4D476EQ36539092-6DCCDCEE-E55A-4035-9CB9-9477DC7D36CBQ36571388-2F6EC6BE-04EE-4D2F-8F47-A4DC96DACAD4Q36692389-F1D1316D-A2FF-4188-86D2-6CC03E1DF5A9Q36746882-CC2B872E-8B7B-459F-B8E4-06FF00176F68Q36777835-BE751BFB-C203-4D70-A40E-C1136AA04631Q37103923-2F8C8A0F-3794-42F0-8300-0EC822B140F0Q37123133-5019F4CD-0EF9-405C-AC61-D3A94B028F8E
P2860
Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Clinical experience with plasm ...... focusing on T-cell induction.
@ast
Clinical experience with plasm ...... focusing on T-cell induction.
@en
type
label
Clinical experience with plasm ...... focusing on T-cell induction.
@ast
Clinical experience with plasm ...... focusing on T-cell induction.
@en
prefLabel
Clinical experience with plasm ...... focusing on T-cell induction.
@ast
Clinical experience with plasm ...... focusing on T-cell induction.
@en
P2093
P356
P1476
Clinical experience with plasm ...... focusing on T-cell induction.
@en
P2093
Andrew J McMichael
Lucy Dorrell
Nilu Goonetilleke
Tomás Hanke
P356
10.1099/VIR.0.82493-0
P407
P577
2007-01-01T00:00:00Z